HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Pipeline

Late-stage drugs with significant commercial implications

BeOne's Venclexta challenger Beqalzi nets FDA approval as first BCL-2 for mantle cell lymphoma
PipelineFiercePharma ↗
BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique …
May 15, 2026
#ASGCT26: Encoded's gene therapy reduced seizures in Dravet syndrome
PipelineEndpoints News ↗
A gene therapy designed by Encoded Therapeutics reduced seizures by 76% in children with Dravet syndrome, a se…
May 14, 2026
Novo, Lilly tout respective early response and weight loss maintenance data as GLP-1 rivalry intensifies
PipelineFiercePharma ↗
Eli Lilly and Novo Nordisk are building cases for their incretin drugs, both new and old, as attractive weight…
May 14, 2026
STAT+: Gene therapy viruses linked to a boy’s tumor
PipelineSTAT News ↗
The case for Makary as the WOAT, Cassidy's seat at risk ahead of midterms, and other biotech news from The Rea…
May 13, 2026
Alkermes’ Lumryz clears phase 3 in idiopathic hypersomnia, intensifying Jazz rivalry
PipelineBriefing
Three months post-Avadel acquisition, Alkermes’ Lumryz met all endpoints in the phase 3 Revitalyz study for id…
May 13, 2026
STAT+: Scientists link boy’s tumor to gene therapy viruses, in rare finding
PipelineSTAT News ↗
Doctors have linked a boy's tumor to a gene therapy, but say the rare risks need to be weighed against the pro…
May 13, 2026
← Newer Page 5 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.